Stockreport

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen, Inc.  (SRZN) 
PDF -Phase 1a trial demonstrated acceptable safety and tolerability with no reported serious adverse events-Phase 1a data demonstrated target engagement, a pharmacodynamic e [Read more]